We found a considerably high prevalence of university students with positive anti-PT IgG. Given that vaccination against
Pertussis leads to short-term increase in antibody level (
7,
10,
11,
20), the possibility of false positive titers due to previous vaccination seems to be unlikely. As the age of our cases ranged between 17 to 38 years and according to the national immunization schedule of Iran, they had taken the last booster dose of DTP at the age of 4 to 6 years, the elevated anti PT IgG levels were attributed to recent infection with
Bordetellapertussis. Similar to many previous studies (
14,
18,
21-
23), we used different cut-off points of anti-PT IgG levels for estimating the prevalence of
Pertussis infection. A study in Poland (
23) reported the prevalence of
Bordetellapertussis infection according to three cut-off points of 40, 80 and 100 U/mL, reflecting contact with this bacteria in the previous two, three, and 12 months. In this study, the prevalence was reported 7.2%, 6.6% and 5.2%, respectively; whereas in our study, the corresponding figures were 55.4%, 37.7% and 28.4%, respectively. The higher prevalence of infection in our study than that of Poland is suggested to be because our study was conducted in October, the beginning of the academic year in Iran, with its previous 5 months being in spring and summer time, which have the highest prevalence of
Bordetellapertussis. In a survey in Singapore (
24) by using the cut-off point of 5 U/mL, the prevalence of
Pertussis infection was 97% among 18-45 years old persons. It is similar to the prevalence of 98.7% documented in our study. In a study in Turkey, seropositivity in cut-off point of 9 U/mL is reported as 30%, but interestingly at the same cut-off point, 93.2% of our study population were seropositive. This difference probably comes from the routine use of a cellular
Pertussis vaccine in the national immunization program in Turkey instead of the cellular vaccine, which has more efficacy and latency (
25). While the specificity of cut-off point of 94 U/mL for acute infection was estimated 99% in a study in United States (
14), The incidence of acute infection in same cut-off point was 31.6% in our study. However, by using all cut-off points - except than 5 U/mL - the prevalence of
Pertussis infection was significantly different in terms of gender. In a study among Turkish children (
26), IgG titer had no significant correlation with the number of family members, but in another study in Cameroon, (
27) significant differences are reported in IgG titer of children according to the number of family members. In our study, we found significant differences in anti-PT IgG levels in cut-points of 40, 50, and 80 U/mL. We found clear differences in the prevalence of
Bordetellapertussis infection in our study with other reports. A previous study in Iranian young adults was conducted among 424 randomly selected military garrisons, aged 18 to 21 years, in Tehran. By considering a cut point of 20 U/mL, the seropositivity is reported to be 60.6% (
28). The corresponding figure in our study was 74%. Furthermore, a study in Iranian university students was conducted in Hamedan. A number of 163 students were studied, and by considering a cut point of 24 U/mL, the sero-prevalence rate of IgG-PT was 47.67% (
29). It is noteworthy to mention that to have an ideal group for studying the sero-prevalence of IGG-PT, we recruited our study participants at the first day of their entry to university, and before their stay in the crowded environment of dormitories, whereas this point has not been considered in previous studies in Iran. Different cut-off points have been used to determine the seropositivity for
Bordeellapertussis; one of the recent recommendations states that a single serum sample showing anti-PT IgG above 100 U/mL may indicate a recent infection (
30). Regardless to the cut-off point used, studies of various countries revealed a substantially high prevalence of infection with
Bordetellapertussis among adolescents and young adults.
Although the incidence of
Pertussis is reduced in infants and young children - because of the introduction of universal childhood immunization - in countries with high vaccination rates it has been increasing in adolescents and young adults in recent years especially in ages ranging between 35-39 years. An accumulating body of evidence proposes that the current childhood immunization schedule is not efficient and long lasting for eradication of
Pertussis, thus a booster dose of a cellular vaccine is recommended in later life. Several scientific consensus statements, as the American Academy of Pediatrics (
31,
32) have recommended to consider a booster dose in adolescence. The recent recommendations in immunization schedule suggest that adolescents should receive a single dose of Tdap vaccine instead of Td for booster immunization against tetanus, diphtheria, and
Pertussis and the preferred age for Tdap immunizations is 11 through 12 years of age (
31-
38).